04:35 PM EDT, 07/19/2024 (MT Newswires) -- Longeveron ( LGVN ) said Friday it has closed a registered direct offering of about 2.2 million class A shares at $4.025 per share, raising about $9 million to advance its drug candidate Lomecel-B and for other general corporate purposes.

The company also issued warrants to buy up to about 2.2 million class A shares to the investors, the company said.

Price: 3.3100, Change: +0.02, Percent Change: +0.61